Novartis, Bayer Near Deal Over Hemophilia Drugs
The vaccines division of Swiss drugmaker Novartis AG has reached a settlement in principle with Bayer Healthcare LLC in a patent infringement suit over Bayer hemophilia drugs Kogenate and Helixate....To view the full article, register now.
Already a subscriber? Click here to view full article